For decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. These continue to be critical mainstays of treatment, but new categories of treatment have recently helped transform the treatment picture for people with cancer.
Since 2017, six CAR T-cell therapies have been approved by the Food and Drug Administration (FDA). All are approved for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.
Currently, after years of painstaking research, CAR T-cell therapies have entered the mainstream of cancer treatment, said Steven Rosenberg, M.D., Ph.D., chief of the Surgery Branch in NCI’s Center for Cancer Research (CCR), an immunotherapy and CAR T-cell therapy pioneer.
“[CAR T cells] are now widely available in the United States and other countries and have become a standard treatment for patients with aggressive lymphomas,” Dr. Rosenberg said. “They have become a part of modern medicine.”
The clinical outcomes and financial details of CAR T-cell therapy will be discussed with you by your care team.
The above information as seen on the NIH/National Cancer Institute website, https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
The National Bone Marrow Transplant Link, established in 1992, strives to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing free programs and personalized support services.
The information in these resources should not be construed as medical advice. Please consult with your health care provider regarding your medical decisions and treatment. The listed resources are not intended to be endorsements.